Number of patients | n (%) | 95% CI* of prevalence (%) | Neurological symptoms (%) | ||
Yes (n=8) | No (n=62) | p Value | |||
Pleocytosis (WBC>5 cells/μl) | 4 (5.7) | 1 to 14 | 0 | 4 (6.5) | 0.459 |
Protein elevation (>0.45 g/l) | 57 (81.4) | 71 to 89 | 7 (87.5) | 50 (80.6) | 0.639 |
CSF IgG index elevated (>0.85) | 0 | 0 to 6 | 0 | 0 | |
CSF TPHA/FTA-ABS positive | 3 (4.3) | 1 to 12 | 1 (12.5) | 2 (3.2) | 0.223 |
CSF VDRL positive | 0 | 0 to 6 | 0 | 0 |
CSF, cerebrospinal fluid; FTA-ABS; fluorescent treponemal antibody absorption; TPHA, Treponema pallidum haemeagglutination; VDRL, Venereal Disease Research Laboratory.
↵* CI was calculated by modified Wald method.